These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16691078)

  • 1. Unexpected improvement of sexual dysfunction during atazanavir therapy.
    Colebunders R; Moerman F; Nöestlinger C
    AIDS; 2006 May; 20(8):1209-10. PubMed ID: 16691078
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected improvement of sexual dysfunction during atazanavir therapy.
    Bernal E; Masiá M; Padilla S; Gutiérrez F
    AIDS; 2005 Sep; 19(13):1440-1. PubMed ID: 16103782
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917
    [No Abstract]   [Full Text] [Related]  

  • 8. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 10. Sexual dysfunction in the highly active antiretroviral therapy era.
    Collazos J
    AIDS Rev; 2007; 9(4):237-45. PubMed ID: 18219367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 14. Atazanavir urolithiasis.
    Chang HR; Pella PM
    N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of renal stones in patients treated with atazanavir.
    Tattevin P; Revest M; Chapplain JM; Ratajczak-Enselme M; Arvieux C; Michelet C
    Clin Infect Dis; 2013 Apr; 56(8):1186. PubMed ID: 23300244
    [No Abstract]   [Full Text] [Related]  

  • 19. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 20. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.